Harbin Pharmaceutical president Lu Chuanyou detained in graft probe

Harbin Pharmaceutical Group Co Ltd said director and president Lu Chuanyou has been placed under detention by a supervisory commission, hitting the northeastern Chinese drugmaker as the country's healthcare graft crackdown widens.

The terse exchange filing, published on the evening of Oct 11, puts the executive who runs the company's sales machine at the centre of a probe. Lu sat atop the channel that decides hospital access, distributor margins and rebates for hundreds of the company's mature generic drugs.

Harbin Pharmaceutical said its board and management are operating normally and that the detention has not materially affected day-to-day production. Investors are likely to treat that cautiously: the president is the operating core of the business, and the company is still trying to climb out of losses.

A state-controlled pharma flagship

Harbin Pharmaceutical Group Co Ltd was founded in 1991, lists Hu Xiaofang as legal representative and has registered capital of about 2.519 billion yuan (about $355 million). It has traded on the Shanghai Stock Exchange since 1993.

Harbin Pharmaceutical Group Co Ltd, the unlisted parent, holds 46.58% and is the controlling shareholder, according to corporate records database Tianyancha. The group spans drug research, chemical preparations, biotech, traditional Chinese medicine and wholesale and retail distribution. Its industrial base includes Harbin Pharmaceutical General Factory, Shiyitang and Harbin Pharmaceutical Factory No. 6.

Who is Lu Chuanyou

Unlike executives who rose inside state-owned enterprises, Lu built his career at leading drugmakers and joint ventures, holding senior marketing and management posts at Sanjiu (999) pharmaceutical group and China Resources Pharmaceutical.

He was moved into the director and president role as Harbin Pharmaceutical brought in strategic investors and adopted market-style incentives. In the company's power structure, the chairman handles strategy and coordination with state capital. The president signs off on hospital access for prescription drugs, rebates in over-the-counter channels, wholesale distribution and national agency rights for hundreds of mature generics. That makes him the executive who decides where billions of yuan in sales and rebates flow.

From hospital wards to marketing departments

The detention reflects a shift in China's medical anti-corruption campaign from hospital chiefs to the sales arms of drugmakers, with bribe takers and bribe givers pursued together.

Over the past two years investigators have concentrated on the grey channels drugmakers use to move money: contract sales organisations, fictitious academic conferences and fake invoices cashed out for kickbacks.

Harbin Pharmaceutical's portfolio is weighted towards mature antibiotics, traditional Chinese medicine injections and off-patent drugs. Such products are highly homogenised, and competition is fierce to get them listed on provincial procurement platforms, into medical insurance catalogues and onto hospital formularies.

To sustain prescription volumes, industrial and distribution units built sprawling agent networks and marketing incentive schemes across the country. When a marketing executive or an affiliated chain is implicated by lower-tier distributors or by fallen hospital officials, a supervisory commission with jurisdiction can open a case and order detention under the Supervision Law.

Mixed-ownership strain

Beneath the probe lies a deeper problem: a governance overhaul that never settled. Harbin Pharmaceutical brought in CITIC Capital and other outside investors through mixed-ownership reform, hoping market-style performance targets would loosen rigid state-owned incentives.

Its costly purchase of overseas supplement brand GNC ended in bankruptcy restructuring and billions of yuan in impairment charges. That damaged the company's finances and deepened disagreement among shareholder camps over strategy.

A model built on heavy advertising and light R&D stopped working once centralized drug procurement and generic drug consistency evaluation took hold. Gross margins on core generics and anti-infective products were squeezed, and the innovative pipeline lacks a blockbuster.

Harbin Pharmaceutical then hired professional managers on high pay to engineer a turnaround through supply chains and distribution channels. Aggressive market-style targets clashed with state-owned risk controls, leaving room for grey dealings. Frequent changes of executives and factions failed to deliver on performance pledges, and internal oversight and compliance checks developed serious gaps.

The test ahead

The 2.519 billion yuan in registered capital recorded by Tianyancha traces a company that has supplied Chinese medicine cabinets for three decades and is now struggling for breath through an industry shakeout and a regulatory storm.

The detention is a bucket of cold water for a company trying to leave losses behind. With Beijing pressing the whole pharmaceutical supply chain to meet compliance standards, shareholders and the public now want to know whether Harbin Pharmaceutical can cut out the sales-with-kickbacks and crude channel-rebate model it has relied on for so long.